Cargando…
Effects of bradykinin on venous capacitance in health and treated chronic heart failure
In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzy...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636358/ https://www.ncbi.nlm.nih.gov/pubmed/18798730 http://dx.doi.org/10.1042/CS20080096 |
_version_ | 1782164291169812480 |
---|---|
author | Gunaruwan, Prasad Maher, Abdul Williams, Lynne Sharman, James Schmitt, Matthias Campbell, Ross Frenneaux, Michael |
author_facet | Gunaruwan, Prasad Maher, Abdul Williams, Lynne Sharman, James Schmitt, Matthias Campbell, Ross Frenneaux, Michael |
author_sort | Gunaruwan, Prasad |
collection | PubMed |
description | In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzyme) inhibitors] (n=16) and ARBs (angiotensin receptor blockers) (n=14). We used radionuclide plethysmography to examine the effects of bradykinin and of the bradykinin antagonists B9340 [B1 (type 1)/B2 (type 2) receptor antagonist] and HOE140 (B2 antagonist). Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3±2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3±3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8±7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups). In contrast, while the increase in blood flow in healthy volunteers (maximum 362±9%, P<0.001) and in ACEI-treated CHF patients (maximum 376±12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335±7%, P<0.001; P<0.05 for the difference between groups). Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients. In conclusion, bradykinin does not contribute to basal venous tone in health, but in ACEI-treated chronic heart failure it does. In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial responses are reduced compared with healthy controls. Bradykinin-mediated vascular responses in both health and heart failure are mediated by the B2, rather than the B1, receptor. |
format | Text |
id | pubmed-2636358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-26363582009-02-10 Effects of bradykinin on venous capacitance in health and treated chronic heart failure Gunaruwan, Prasad Maher, Abdul Williams, Lynne Sharman, James Schmitt, Matthias Campbell, Ross Frenneaux, Michael Clin Sci (Lond) Research Article In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzyme) inhibitors] (n=16) and ARBs (angiotensin receptor blockers) (n=14). We used radionuclide plethysmography to examine the effects of bradykinin and of the bradykinin antagonists B9340 [B1 (type 1)/B2 (type 2) receptor antagonist] and HOE140 (B2 antagonist). Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3±2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3±3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8±7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups). In contrast, while the increase in blood flow in healthy volunteers (maximum 362±9%, P<0.001) and in ACEI-treated CHF patients (maximum 376±12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335±7%, P<0.001; P<0.05 for the difference between groups). Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients. In conclusion, bradykinin does not contribute to basal venous tone in health, but in ACEI-treated chronic heart failure it does. In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial responses are reduced compared with healthy controls. Bradykinin-mediated vascular responses in both health and heart failure are mediated by the B2, rather than the B1, receptor. Portland Press Ltd. 2009-02-02 2009-03-01 /pmc/articles/PMC2636358/ /pubmed/18798730 http://dx.doi.org/10.1042/CS20080096 Text en © 2009 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by-nc/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Gunaruwan, Prasad Maher, Abdul Williams, Lynne Sharman, James Schmitt, Matthias Campbell, Ross Frenneaux, Michael Effects of bradykinin on venous capacitance in health and treated chronic heart failure |
title | Effects of bradykinin on venous capacitance in health and treated chronic heart failure |
title_full | Effects of bradykinin on venous capacitance in health and treated chronic heart failure |
title_fullStr | Effects of bradykinin on venous capacitance in health and treated chronic heart failure |
title_full_unstemmed | Effects of bradykinin on venous capacitance in health and treated chronic heart failure |
title_short | Effects of bradykinin on venous capacitance in health and treated chronic heart failure |
title_sort | effects of bradykinin on venous capacitance in health and treated chronic heart failure |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636358/ https://www.ncbi.nlm.nih.gov/pubmed/18798730 http://dx.doi.org/10.1042/CS20080096 |
work_keys_str_mv | AT gunaruwanprasad effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure AT maherabdul effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure AT williamslynne effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure AT sharmanjames effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure AT schmittmatthias effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure AT campbellross effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure AT frenneauxmichael effectsofbradykininonvenouscapacitanceinhealthandtreatedchronicheartfailure |